MOUNT PLEASANT – The experimental antibody cocktail drug administered to President Trump following his COVID-19 positive diagnosis was developed by Regeneron Pharmaceuticals, a Westchester County-based company.
On September 29, the company announced “the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19.”
Regeneron has received millions of dollars in state aid in recent years through the economic development department.
Among the pharmaceuticals it has developed is Dupixent, as a treatment for atopic dermatitis.
